Compare REGN & F Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | F |
|---|---|---|
| Founded | 1988 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3B | 51.3B |
| IPO Year | 1991 | N/A |
| Metric | REGN | F |
|---|---|---|
| Price | $730.17 | $13.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 15 |
| Target Price | ★ $799.33 | $12.95 |
| AVG Volume (30 Days) | 826.1K | ★ 50.2M |
| Earning Date | 01-30-2026 | 02-04-2026 |
| Dividend Yield | 0.47% | ★ 5.43% |
| EPS Growth | 2.88 | ★ 33.19 |
| EPS | ★ 41.59 | 1.17 |
| Revenue | $14,247,800,000.00 | ★ $189,588,000,000.00 |
| Revenue This Year | $2.08 | N/A |
| Revenue Next Year | $6.82 | $0.56 |
| P/E Ratio | $17.84 | ★ $11.81 |
| Revenue Growth | 2.89 | ★ 3.75 |
| 52 Week Low | $476.49 | $8.44 |
| 52 Week High | $821.11 | $14.50 |
| Indicator | REGN | F |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 51.35 |
| Support Level | $743.94 | $13.96 |
| Resistance Level | $766.64 | $14.13 |
| Average True Range (ATR) | 20.38 | 0.27 |
| MACD | -8.52 | -0.01 |
| Stochastic Oscillator | 3.37 | 39.93 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 10% share in the UK, and under 2% share in China including unconsolidated affiliates. Sales in the US made up about 68% of 2024 total company revenue. Ford has about 171,000 employees, including about 56,500 UAW employees, and is based in Dearborn, Michigan.